Pb2107: Evolution of Selection Criteria for Phase 3 Clinical Trials in Multiple Myeloma.

Abstract

Between 47-72% of patients diagnosed with multiple myeloma (MM) would be excluded from participating in clinical trials due to restrictive selection criteria. This is of particular interest in phase 3 trials, in which some clinical trials are focused on authorization approvals and other to serve as a mirror for real world clinical setting. Since 2017, the ASCO-Friends of Cancer Research published recommendations to modernize the inclusion criteria and favor the inclusion of patients in clinical trials.